ARTICLE | Company News

Xencor revises XmAb5871 deal with Amgen

October 30, 2014 2:26 AM UTC

Xencor Inc. (NASDAQ:XNCR) renegotiated its deal with Amgen Inc. (NASDAQ:AMGN) related to autoimmune candidate XmAb5871. Xencor terminated the companies' original deal in which the bellwether had an option to license exclusive, worldwide rights to XmAb5871 upon completion of a Phase II trial to treat rheumatoid arthritis (RA).

Xencor said it wants to develop the antibody for diseases with higher unmet need. Thus, Xencor plans to instead develop XmAb5871 for other autoimmune diseases including the rare disorder IgG4-related disease. Xencor granted Amgen the right of first negotiation to license XmAb5871. ...